Isotretinoin-associated acne fulminans: A multicentre, retrospective study of the European Academy of Dermatology and Venereology Task Force on Acne, Rosacea and Hidradenitis Suppurativa.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
29 Aug 2023
29 Aug 2023
Historique:
received:
09
06
2023
accepted:
18
08
2023
pubmed:
30
8
2023
medline:
30
8
2023
entrez:
29
8
2023
Statut:
aheadofprint
Résumé
Acne fulminans (AF) is a rare severe acne entity. Although occasionally reported, it is unclear whether AF development is associated with oral isotretinoin treatment. To investigate the occurrence of isotretinoin-associated AF, clinical characteristics and prognosis at follow-up. An international, multicentre, retrospective study was performed in eight hospitals following the call of the EADV Task Force on Acne, Rosacea and Hidradenitis Suppurativa (ARHS). Characteristics of patients treated with isotretinoin before the development of AF (isotretinoin-associated acne fulminans, IAF) were compared with non-IAF (NAF). Forty-nine patients diagnosed with AF from 2008 to 2022 were included (mean age 16.4 years, SD 2.9, 77.6% male). Αrthralgias/arthritis occurred in 11 patients (22.9%). AF occurred without any previous acne treatment in 26.5% of the patients. Overall, 28 patients (57.1%) developed AF after oral isotretinoin intake (IAF group), while the remaining 21 patients (42.9%) developed AF without previous oral isotretinoin administration (NAF group). IAF occurred after a median duration of isotretinoin treatment of 45 days (IQR: 30, 90). Patients with IAF were more frequently male compared to patients with NAF (89.3% vs. 61.9%, respectively, p = 0.023). There were no differences in patients with IAF versus NAF in patient age, the duration of pre-existing acne, a family history of AF, the distribution of AF lesions or the presence of systemic symptoms or arthralgias. Regarding the management of AF, patients with IAF were treated more frequently with prednisolone (96.2%) compared to those with NAF (70%; p = 0.033) and less frequently with isotretinoin (32.1%) compared to NAF (85.7%; p < 0.001). At a median follow-up of 2.2 years, 76.4% of patients were free of AF and scarring was present in all patients. No specific clinical or demographic characteristics of IAF compared with NAF could be detected, a fact that does not support IAF as a district clinical entity.
Sections du résumé
BACKGROUND
BACKGROUND
Acne fulminans (AF) is a rare severe acne entity. Although occasionally reported, it is unclear whether AF development is associated with oral isotretinoin treatment.
OBJECTIVES
OBJECTIVE
To investigate the occurrence of isotretinoin-associated AF, clinical characteristics and prognosis at follow-up.
METHODS
METHODS
An international, multicentre, retrospective study was performed in eight hospitals following the call of the EADV Task Force on Acne, Rosacea and Hidradenitis Suppurativa (ARHS). Characteristics of patients treated with isotretinoin before the development of AF (isotretinoin-associated acne fulminans, IAF) were compared with non-IAF (NAF).
RESULTS
RESULTS
Forty-nine patients diagnosed with AF from 2008 to 2022 were included (mean age 16.4 years, SD 2.9, 77.6% male). Αrthralgias/arthritis occurred in 11 patients (22.9%). AF occurred without any previous acne treatment in 26.5% of the patients. Overall, 28 patients (57.1%) developed AF after oral isotretinoin intake (IAF group), while the remaining 21 patients (42.9%) developed AF without previous oral isotretinoin administration (NAF group). IAF occurred after a median duration of isotretinoin treatment of 45 days (IQR: 30, 90). Patients with IAF were more frequently male compared to patients with NAF (89.3% vs. 61.9%, respectively, p = 0.023). There were no differences in patients with IAF versus NAF in patient age, the duration of pre-existing acne, a family history of AF, the distribution of AF lesions or the presence of systemic symptoms or arthralgias. Regarding the management of AF, patients with IAF were treated more frequently with prednisolone (96.2%) compared to those with NAF (70%; p = 0.033) and less frequently with isotretinoin (32.1%) compared to NAF (85.7%; p < 0.001). At a median follow-up of 2.2 years, 76.4% of patients were free of AF and scarring was present in all patients.
CONCLUSIONS
CONCLUSIONS
No specific clinical or demographic characteristics of IAF compared with NAF could be detected, a fact that does not support IAF as a district clinical entity.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 European Academy of Dermatology and Venereology.
Références
Jansen T, Plewig G. Acne fulminans. Int J Dermatol. 1998;37(4):254-257.
Thomson KF, Cunliffe WJ. Acne fulminans ‘sine fulminans’. Clin Exp Dermatol. 2000;25(4):299-301.
Dessinioti C, Katsambas A. Difficult and rare forms of acne. Clin Dermatol. 2017;35(2):138-146.
Massa AF, Burmeister L, Bass D, Zouboulis CC. Acne fulminans: treatment experience from 26 patients. Dermatology. 2017;233(2-3):136-140.
Bocquet-Tremoureux S, Corvec S, Khammari A, Dagnelie MA, Boisrobert A, Dreno B. Acne fulminans and Cutibacterium acnes phylotypes. J Eur Acad Dermatol Venereol. 2020;34(4):827-833.
Burns RE, Colville JM. Acne conglobata with septicaemia. Arch Dermatol. 1959;79:361-363.
Tan BB, Lear JT, Smith AG. Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone. Clin Exp Dermatol. 1997;22(1):26-27.
Sarifakioglu E, Onur O, Kart H, Yilmaz AE. Acute myopathy and acne fulminans triggered by isotretinoin therapy. Eur J Dermatol. 2011;21(5):794-795.
Sanchez-Velazquez A, Falkenhain-Lopez D, Arroyo-Andres J, Montero-Menarguez J, Garcia-Donoso C, Postigo-Llorente C. Apremilast: a novel adjuvant treatment for refractory isotretinoin-induced acne fulminans. Dermatol Ther. 2022;35(8):e15637.
Mehrany K, Kist JM, Weenig RH, Witman PM. Acne fulminans. Int J Dermatol. 2005;44(2):132-133.
Picone V, Potestio L, Fabbrocini G, Monfrecola G, Marasca C. A case of acne fulminans successfully treated with photodynamic therapy. Photodermatol Photoimmunol Photomed. 2022;38(4):401-403.
Li AW, Antaya RJ. Isotretinoin-induced acne fulminans without systemic symptoms with concurrent exuberant granulation tissue. Pediatr Dermatol. 2018;35(2):257-258.
Legal K, Misery L. Isotretinoin-induced acne fulminans without systemic symptoms treated successfully with oral dapsone. Acta Derm Venereol. 2020;100(1):adv00036.
Lee G, Ferri-Huerta R, Greenberg KB, Somers KE. Acne fulminans in a transgender boy after an increase in testosterone dosage. JAAD Case Rep. 2022;21:32-34.
Kraus SL, Emmert S, Schon MP, Haenssle HA. The dark side of beauty: acne fulminans induced by anabolic steroids in a male bodybuilder. Arch Dermatol. 2012;148(10):1210-1212.
Trave I, Micalizzi C, Molle M, Castelli R, Cozzani E, Parodi A. Acne fulminans induced by lymecycline in a patient with hidradenitis suppurativa: a case report. Case Rep Dermatol. 2022;14(2):112-116.
Miguel D, Tittelbach J, Elsner P. A dramatic case of acne fulminans responding to adalimumab. J Dtsch Dermatol Ges. 2019;17(8):837-838.
Kim SY, Jung SK, Lee SG, Yi SM, Kim JH, Kim IH. Acne fulminans with osteolytic change in metaphysis of distal radius. Int J Dermatol. 2016;55(5):571-573.
Jansen T, Romiti R, Plewig G. Acute severe acne in a female patient (acne fulminans?). Br J Dermatol. 1999;141(5):945-947.
Hao J, Wang T. 5-Aminolevulinic acid photodynamic therapy and isotretinoin for treatment of drug-induced acne fulminans in a patient with idiopathic thrombocytopenic purpura. Photodiagnosis Photodyn Ther. 2020;29:101630.
Gualtieri B, Tonini A, Panduri S, Chiricozzi A, Romanelli M. Acne fulminans associated with lymecycline intake: a case report. Clin Cosmet Investig Dermatol. 2018;11:403-405.
Giavedoni P, Mascaro-Galy JM, Aguilera P, Estrach-Panella T. Acne fulminans successfully treated with cyclosporine and isotretinoin. J Am Acad Dermatol. 2014;70(2):e38-e39.
Furukawa F, Makino T, Mori S, Shimizu T. Successful treatment of acne fulminans with the combination of prednisolone and diaminodiphenylsulfone. J Dermatol. 2021;48(2):e120-e121.
Alakeel A, Ferneiny M, Auffret N, Bodemer C. Acne fulminans: case series and review of the literature. Pediatr Dermatol. 2016;33(6):e388-e392.
Karvonen SL. Acne fulminans: report of clinical findings and treatment of twenty-four patients. J Am Acad Dermatol. 1993;28(4):572-579.
Seukeran DC, Cunliffe WJ. The treatment of acne fulminans: a review of 25 cases. Br J Dermatol. 1999;141(2):307-309.
Kregiel M, Zuchowska A, Tomaszewska K, Wojciechowska A, Jędrowiak A, Tabara K, et al. Acne fulminans in the course of oral isotretinoin treatment. Presentation of cases. Our Dermatol Online. 2017;8(2):210-214.
Kouotou EA, Nguena Feungue U, Tounouga DN, Trojjet S, Mokni M, Osman AB, et al. Severity of acne and quality of life of patients treated at Cameroonian hospitals (sub-Saharan Africa). Our Dermatol Online. 2023;14(1):16-22.
Greywal T, Zaenglein AL, Baldwin HE, Bhatia N, Chernoff KA, del Rosso JQ, et al. Evidence-based recommendations for the management of acne fulminans and its variants. J Am Acad Dermatol. 2017;77(1):109-117.
Williamson DM, Cunliffe WJ, Gatecliff M, Scott DG. Acute ulcerative acne conglobata (acne fulminans) with erythema nodosum. Clin Exp Dermatol. 1977;2(4):351-354.
Duchatelet S, Join-Lambert O, Delage M, Miskinyte S, Guet-Revillet H, Lam T, et al. Remission of chronic acne fulminans and severe hidradenitis suppurativa with targeted antibiotherapy. JAAD Case Rep. 2019;5(6):525-528.
Join-Lambert O, Duchatelet S, Delage M, Miskinyte S, Coignard H, Lemarchand N, et al. Remission of refractory pyoderma gangrenosum, severe acne, and hidradenitis suppurativa (PASH) syndrome using targeted antibiotic therapy in 4 patients. J Am Acad Dermatol. 2015;73(5 Suppl 1):S66-S69.
Duchatelet S, Miskinyte S, Join-Lambert O, Ungeheuer MN, Francès C, Nassif A, et al. First nicastrin mutation in PASH (pyoderma gangrenosum, acne and suppurative hidradenitis) syndrome. Br J Dermatol. 2015;173(2):610-612.
Zouboulis CC, Bechara FG, Dickinson-Blok JL, Gulliver W, Horváth B, Hughes R, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19-31.
Iqbal M, Kolodney MS. Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol. 2005;52(5 Suppl 1):S118-S120.
Maitrepierre F, Marzano AV, Lipsker D. A unified concept of acne in the PAPA Spectrum disorders. Dermatology. 2021;237(5):827-834.
Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell. 2010;140(6):784-790.
Oranges T, Insalaco A, Diociaiuti A, Carnevale C, Strippoli R, Zambruno G, et al. Severe osteoarticular involvement in isotretinoin-triggered acne fulminans: two cases successfully treated with anakinra. J Eur Acad Dermatol Venereol. 2017;31(6):e277-e279.
Barry KK, Neale HD, Hawryluk EB. Tumor necrosis factor-alpha inhibitors and acne fulminans: friend or foe? Pediatr Dermatol. 2022;40:678-680.